@article {Karikari2020.07.15.20154237, author = {Thomas K. Karikari and Andr{\'e}a L. Benedet and Nicholas J. Ashton and Juan Lantero Rodriguez and Anniina Snellman and Marc Su{\'a}rez-Calvet and Paramita Saha Chaudhuri and Firoza Lussier and Hlin Kvartsberg and Alexis Moscoso Rial and Tharick A. Pascoal and Ulf Andreasson and Michael Sch{\"o}ll and Pedro Rosa-Neto and Kaj Blennow and Henrik Zetterberg and for the Alzheimer{\textquoteright}s Disease Neuroimaging Initiative}, title = {Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer{\textquoteright}s Disease Neuroimaging Initiative}, elocation-id = {2020.07.15.20154237}, year = {2020}, doi = {10.1101/2020.07.15.20154237}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer{\textquoteright}s disease (AD), their broad implementation in clinical and trial settings are restricted by high cost and limited accessibility. Plasma phosphorylated-tau181 (p-tau181) is a promising blood-based biomarker that is specific for AD, correlates with cerebral Aβ and tau pathology, and predicts future cognitive decline. In this study, we report the performance of p-tau181 in \>1,000 individuals from the Alzheimer{\textquoteright}s Disease Neuroimaging Initiative (ADNI), including cognitively unimpaired (CU), mild cognitive impairment (MCI) and AD dementia patients characterized by Aβ PET. We confirmed that plasma p-tau181 is increased at the preclinical stage of Alzheimer and further increases in MCI and AD dementia. Individuals clinically classified as AD dementia but having negative Aβ PET scans did not show increased plasma p-tau181. Despite being a multicenter study, plasma p-tau181 demonstrated high diagnostic accuracy to identify AD dementia (AUC=85.3\%; 95\% CI, 81.4\%-89.2\%), as well as to distinguish between Aβ- and Aβ+ individuals along the Alzheimer{\textquoteright}s continuum (AUC=76.9\%; 95\% CI, 74.0\%-79.8\%). Higher baseline concentrations of plasma p-tau181 accurately predicted future dementia and performed comparably to the baseline prediction of CSF p-tau181. Longitudinal measurements of plasma p-tau181 revealed low intra-individual variability, which could be of potential benefit in disease-modifying trials seeking a measurable response to a therapeutic target. This study adds significant weight to the growing body of evidence in the use of plasma p-tau181 as a non-invasive diagnostic and prognostic tool for AD, regardless of clinical stage, which would be of great benefit in clinical practice and a large cost-saving in clinical trial recruitment.Competing Interest StatementKB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers. H.Z. has served at scientific advisory boards for Wave, Samumed, CogRx, Siemens Healthineers and Roche Diagnostics and has given open lectures for Alzecure, Fujirebio, and Biogen. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The other authors declare no competing interests.Funding StatementFull funding details are given in the article text.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was provided by the enrolled participants or their authorized representatives. The ADNI study was approved by the local Institutional Review Boards at the participating centers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe files used in preparing this manuscript are publicly available from http://adni.loni.usc.edu/. All data is available in the main text or the supplementary materials.}, URL = {https://www.medrxiv.org/content/early/2020/07/16/2020.07.15.20154237}, eprint = {https://www.medrxiv.org/content/early/2020/07/16/2020.07.15.20154237.full.pdf}, journal = {medRxiv} }